+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and growth factors regulate the aggressiveness and proliferative activity of keratocystic odontogenic tumors



Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and growth factors regulate the aggressiveness and proliferative activity of keratocystic odontogenic tumors



Oral Surgery Oral Medicine Oral Pathology and Oral Radiology 114(4): 487-496



The objective of this preliminary study was to evaluate the expression of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and growth factors in keratocystic odontogenic tumors (KOTs). The expression of MMPs, TIMPs, growth factors, and the extracellular signal-regulated kinase (ERK) 1/2 signaling pathway were assessed by immunohistochemistry in 15 cases of KOT and 4 cases of calcifying cystic odontogenic tumor (CCOT). KOT samples expressed significantly higher amounts of MMPs, TIMPs, growth factors, epidermal growth factor receptor (EGFR), and ERK compared with CCOT samples, with the exception of MMP-2 and TIMP-1. MMP-9, TIMP-2, EGF and transforming growth factor α act together and likely regulate the proliferation and aggressiveness of KOT. ERK-1/2 serves as the transducer of signals generated by these proteins, which signal through the common receptor, EGFR. This process may be related to the increased proliferation and aggressiveness observed in KOT.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054275392

Download citation: RISBibTeXText

PMID: 22986244

DOI: 10.1016/j.oooo.2012.06.011


Related references

The influence of risk factors for malignant tumors of maxillo-facial area on the expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients of elderly and senile age period. Advances in Gerontology 27(3): 468-471, 2014

The activity of matrix metalloproteinases (MMPS) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. Journal of Veterinary Medical Science 68(2): 105-111, 2006

Antidepressant treatments regulate matrix metalloproteinases-2 and -9 (MMP-2/MMP-9) and tissue inhibitors of the metalloproteinases (TIMPS 1-4) in the adult rat hippocampus. Synapse 62(8): 590-600, 2008

Immunohistochemical analysis of matrix metalloproteinases (1, 2, and 9), Ki-67, and myofibroblasts in keratocystic odontogenic tumors and pericoronal follicles. Journal of Oral Pathology & Medicine 43(4): 282-288, 2014

Immunohistochemical analysis of matrix metalloproteinases (1, 2, and 9), Ki-67, and myofibroblasts in keratocystic odontogenic tumors and pericoronal follicles. Journal of Oral Pathology and Medicine 43(4): 282-288, 2014

Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23(6): 1341-1344, 1996

Differential regulation of the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases by cytokines and growth factors in bovine endometrial stromal cells and trophoblast cell line BT-1 in vitro. Biology of Reproduction 68(4): 1276-1281, 2003

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in some endocrine organs and their tumors. Endocrine Pathology 10(1): 15-26, 1999

Human aqueous humor levels of transforming growth factor-β2: Association with matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases. Biomedical Reports 7(6): 573-578, 2017

Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by basic fibroblast growth factor and dexamethasone in periodontal ligament cells. Journal of Periodontal Research 44(6): 794-802, 2009

Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. Journal of Urology 179(6): 2447-2455, 2008

Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells. Journal of Cellular Physiology 185(2): 207-214, 2000

The protein expression difference of transforming growth factor beta1, matrix metalloproteinases 1,7,9 and tissue inhibitors of matrix metalloproteinases-1 between chronic rhinosinusitis, nasal polyps and normal mucosa tissues. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19(14): 633-635, 2005

Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli. Bone (New York) 28(3): 303-309, 2001

Changes of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the serum of patients with autoimmune diseases association with age and disease activity. Clinical Chemistry & Laboratory Medicine 42(8): 880-888, 2004